Overview

Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC

Status:
Completed
Trial end date:
2019-11-12
Target enrollment:
Participant gender:
Summary
A randomized, double blind, multicenter phase3 study .
Phase:
Phase 3
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Collaborator:
WuXi CDS Clinical Research (Shanghai) Co.Ltd.
Treatments:
Albumin-Bound Paclitaxel
Bevacizumab
Carboplatin
Paclitaxel